Twelves CJ, Dobbs NA, Aldhous M, Harper PG, Rubens RD, Richards MA: Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer 302
Twentyman PR → Müller MR

Urakawa N → Hirano S-I
Urréchaga E → Buesa JM

VanDellen AF → Skapek SX
v de Velde CJH → Marinelli A
Verbist JF → Roussakis C
Verdegaal EME → Los G
Verdier-Pinard P → Wright M
Villani F, Galimberti M, Zunino F, Monti E, Rozza A, Lanza E, Favalli L, Poggi P: Prevention of Doxorubicin-induced cardiomyopathy by reduced glutathione 365
Vogelzang NJ → Vokes EE
Vokes EE, Raschko JW, Vogelzang NJ, Warfield EE, Ratain MJ, Doroshow JH, Schilsky RL: Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study 69
Vokes EE → Fleming GF
Vreeken JAC → Marinelli A
Vries EGE de → Jong S de

Wahlin A, Hörnsten P, Hedenus M, Malm C: Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia 480
Waidelich P → Ehninger G
Wallin I → Hassan M
Wampler GL → Srimuninnimit V
Ward R → Workman P
Warfield EE → Vokes EE
Watanabe M → Nakajima T
Weislau U → Boos J
Weitman SD, Kato GJ, Barbosa JL, Kamen BA: Low-dose methotrexate therapy for hepatoblastoma 233
Westerhof GR → Jansen G
Wick MM → Lee M-M
Wilke H-J → Freund M
Willassen NP → Bremnes RM
Williamson SK → Grunberg SM
Wist E → Bremnes RM
Workman P, Newman HFV, Bleehen NM, Ward R, Smithen CE: Lack of stereoselectivity in the pharmacokinetics and metabolism of the radiosensitizer Ro 03-8799 in man 118
Wright KA → Müller MR
Wright M, Garès M, Verdier-Pinard P, Moisand A, Berlion M, Legrand JJ, Bizzari JP: Differential in vitro action of S-12363, a new vinblastine derivative, and of its epimer on microtubule proteins 434

Yaguchi S-I → Narita T
Yamada N → Nakajima T
Yasuoka M → Kawato Y
Yefenof E → Naftalovich S
Yokokura T → Kawato Y
Yokoyama K → Nakajima T

Zera RT → Roberts JC
Zijlstra JG → Jong S de
Zunino F → Villani F
Zwi LJ → Ching L-M

Indexed in *Current Contents*

Subject index of volume 28

ACNU 145
Acute myeloid leukaemia 74
Adipose tissue 361
Adriamycin 102
Advanced breast cancer 402
Advanced gastric cancer 313
Age 130
Alkylating activity 441
Alprazolam 77
Amsacrine 377
Antagonists 470
Anthracycline resistance 93
Anthrapyrazole biantrazole 55
Antibodies 185
Anti-emetic 231, 470
Antifolate 331
Antileukemic activity 339
Antioxidant 228
Antitumor activity 192, 235, 293, 351, 384
Antitumor agent 409, 414
Arabinoside 74
Ara-C 487
Azathioprine 7

Batanopride 226
BCNU 293
Benzoylphenylurea 351
Bis (2,6-dioxopiperazine) 235
Bistramide A 283
Bleomycin 22, 105, 357
Brain tumor 308
Breast cancer 255, 302
Busulphan 130
Buthionine sulfoximine 15

Calcitonin spray 311
Camptothecin derivative 192
Cancer 81
Canine metabolism 33
Carboplatin 159, 308, 391, 397
Cardiomyopathy 365
Cardiovascular system 266
C1210 cells 339
CCRF-CEM leukemia cells 115
Cervical cancer 391
Chemosensitivity 420
Chemotherapy 81, 139, 147, 199, 217, 231, 313, 319, 470, 480
Children 81, 455
Chlorambucil 205
Chronopharmacology 130
CI941 55
Cisplatin 147, 159, 217, 273, 277, 370, 427
Cisplatin-induced emesis 226
Cisplatin-modified DNA 185
Colon cancer cells 259
Combined chemotherapy regimen 484
CT scan 319
Cutaneous T cell lymphoma 344
Cyclophosphamide 153, 166, 171, 397
L-Cysteine 166
Cytarabine 480
Cytodieresis 283
Cytokines 420
Cytosine 74
Cytosine arabinoside 484
Cytotoxicity 251, 273, 448

Daunorubicin 171, 480
Dexamethasone 231
5,10-Dideazatetrahydrofolic acid 39, 115
Differentiation 39
Dipyridamole 51
Distribution 7
Doxorubicin 302, 365
Drug resistance 461
Drug stability 298

Edatrexate 199
Enantiomers 455
Encapsulation 259
Epidermal cells 181
Epimer 434
Epirubicin 63, 220, 465
Erythroid 102
Estramustine 361
Estrogen receptor 255
Estromustine 361
Etanidazole 153
Etoposide 59, 214, 405, 487

Ferret 470
Flavone-8-acetic acid 409, 414
Fluorodeoxyrudine 69
5-Fluoro-2′-deoxyuridine 241
5-Fluorouracil 123, 217, 251, 448
Fluosol-DA/Carbogen 45
Folate compounds 115
Folinic acid 448
Fostriecin 461
Fotemustine 293, 448
FSallC fibrosarcoma 45

Glutathione 166, 273, 277, 365
Glycoprotein 93
GR63178A 27

Hematologic toxicity 397
Hepatoblastoma 233
Hexamethylene bisacetamide 33
High-dose 109
High-dose cisplatin 211
High-dose DTIC 475
Histamine 266
HL-60 cells 93
HO-221 351
HPLC 22, 27
5-HT_3 470
7-Hydroxymethotrexate 377
Hypercalcaemia 311
Hyperthermia 251

ICI D1694 331
Ifosfamide 142, 298, 455
Inactive metabolites 455
Infusion 69
Interferon 142
Intraperitoneal chemotherapy 159
Iproplatin 391
Isolated liver perfusion 109

K562 cells 102
Ketoconazole 384
Kinetics 123

Leucovorin rescue 199
Leukemia 39, 487
Lipid peroxidation 427
Liposomal valinomycin 370
Liposomes 259
Lonidamine 45
Lung 147
Lung cancer 199

Malignancy 311
Malignant mesothelioma 319
MAO 33
m-BACOD chemotherapy 135
MCF-7 255
Melphalan 15
Mesothelioma 420
Metabolism 7, 118
Metabolites 27, 123
Metastatic breast cancer 63
Methionine metabolism 484
Methotrexate 150, 181, 233, 377
Methylprednisolone 77
Metoclopramide 77, 226
Mice 15
Microtubule proteins 434
Mitomycin C 109, 147, 228, 405
Mitoxantrone 74, 480
Mitozantrone 402
MST-16 235
Multidrug resistance 259
Multivesicular liposomes 105
Murine L1210 115
Murine tumors 351
Myeloid leukemia 480
Myelotoxicity 465
Myocardial toxicity 171

Nephrotoxicity 81
Nitrosourea 293
Nodules 159
Non-Hodgkin's lymphoma 135
Non-small-cell carcinoma 147
Non-small-cell lung cancer 59, 142, 145, 211, 283, 405
N-Trifluoroacetyladriamycin-14-valerate 1
Nucleotides 185
Nucleoside dialdehydes 339

Oral leucovorin 69
Oral mesna 298
Ovarian carcinoma 370

PALA 51
Pentoxifylline 45
Peplomycin 357
Pharmacodynamics 465
Pharmacokinetics 63, 118, 130, 205, 214, 302, 315, 331, 397, 465, 475
Pharmacology 1, 55
Pharmacology 241
Phase I 59
Phase II 223
Pheochromocytoma 217
Photopheresis 344
Pirarubicin 266
Plasma 22
Plasma pharmacokinetics 409
Platinum analogues 315
Platinum complexes 153
Polyploidy 283
Prednimustine 205, 402
Prednisolone 205
Protein kinase C 102
Psoralens 344
Pulmonary toxicity 357

Quercetin 255
Quinazoline 331

Rat hepatocytes 22
Rat kidney 277
Rat liver 441
Rats 109
Recurrent small-cell cancer 220
Renal microsomes 427
Ro 03-8799 118

Sarcoma 51
L-Cysteine 166
Schedule dependence 235
Sensitivity 181
Sequential 139
Small-cell lung cancer 139
Small-cell lung carcinoma 461
Soft-tissue sarcoma 223
Squamous-cell carcinoma 181
Stereoselectivity 118

T cells 384
Teniposide 147
Tetrahydrofolate inhibitors 39
Tetraplatin 273
Thiazolidine 166
Thiols 277
Thiopurines 7
thio-TEPA 441
Topoisomerase 461
Toxicity 15, 59, 228
Trifluoperazine 384
Trimetrexate 223

Urinary alkalinisation 150
Urotoxicity 166

Vascular dilation 266
V-79 cells 251
Vinblastine 211
Vinblastine derivative 434
Vindesine 405

Walker 256 carcinoma 293
WR compounds 308

Xenografts 192